Aim: Inhaled hypertonic saline increases mucociliary clearance, improves pulmonary function, and decreases exacerbations in cystic fibrosis (CF) but contributes to the already significant treatment burden of CF. Overnight delivery of inhaled medications via a specially designed nasal cannula-aerosol device (Trans-nasal Pulmonary Aerosol Delivery [tPAD]) is an alternative approach. Here, we test whether overnight inhalation of hypertonic saline via tPAD improves mucociliary clearance and assess the tolerability of the device.
| INTRODUCTION
Cystic Fibrosis (CF) is an autosomal recessive disease associated with a single gene, the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which encodes an anion channel on epithelial surfaces. In CF, the absence or dysfunction of CFTR causes airway surface liquid (ASL) dehydration which impairs mucociliary clearance (MCC). CF lung disease is associated with chronic infection and inflammation, lung damage, loss of respiratory function, and premature mortality. [1] [2] [3] [4] [5] [6] Nebulized hypertonic saline (HS) is used extensively as a therapy in CF based on seminal studies that demonstrated increased pulmonary function and decreased exacerbation rates with its use. 7, 8 HS is thought to reverse the osmotic gradients in the ASL, rehydrating mucus, and improving MCC. 7, 9 In current clinical use, HS is inhaled two to four times daily using a nebulizer.
The treatment burden of CF is significant. Patients perform daily, time-consuming airway clearance therapies and nebulize multiple medications. One option for easing this treatment burden is delivery of inhaled medications during sleep using the Transnasal Pulmonary Aerosol Delivery or tPAD device (Parion Sciences, Durham NC)-a device that allows for aerosolization of liquid medication for administration via a modified nasal cannula designed to be worn at night. It includes a liquid reservoir system that allows for extended operation and an air delivery and mixing system that sizes the aerosol for transnasal delivery to the lungs and transports the aerosol through the cannula and into the nares where it is inhaled. Delivery of HS to the airways via tPAD offers a "slow infusion" alternative to traditional nebulizer delivery that may provide prolonged exposure to osmotic gradients when compared to oral inhalation using a standard nebulizer.
In pre-clinical studies, aerosol size at the cannula prongs was 1.81-2.04 μm, volume median diameter (VMD), as measured by laser diffraction. The total saline dose delivered over 8 h was 1371-2047 mg with a 7% HS solution. Pulmonary deposition efficiency of the tPAD device was assessed via deposition scintigraphy. Lung dose was 38 ± 9% of emitted dose, similar to oral inhalation from the Pari LC Star nebulizer. 10 Other more recent studies of tPAD performance are also now available.
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Here, we utilized a functional imaging technique to measure MCC and absorptive clearance (ABS) after overnight delivery of 7% HS from the tPAD device and compared the measurements to a sham treatment night. MCC measurements have been used as a biomarker of therapeutic efficacy in several studies. 7, [12] [13] [14] [15] The technique measures the clearance of non-absorbable radiolabeled particles from the airways, providing a marker of mucus clearance. ABS is a developmental biomarker that measures the paracellular absorption of a small molecule radiopharmaceutical from the airways. ABS is increased in the CF lung 9 and is proportional to ASL absorption in vitro. 16 We also assessed safety and tolerability of tPAD therapy for overnight use.
| MATERIALS AND METHODS

| The tPAD device
The tPAD device includes a 2 LPM air pump, an Aeroneb Pro Nebulizer (Aerogen, Galway, Ireland), a 250 mL liquid reservoir, a liquid collection chamber, and an integrated nebulization chamber (INC) where the aerosol is combined with the flow from the air pump. It also includes electronics allowing for timed device operation for up to 8 h. A systemspecific nasal cannula is attached to the INC and used to deliver the aerosol. For this study the cannula was secured to the subject using a
Wisp nasal mask frame and headgear (Philips Respironics, Murraysville, PA).
| Hypertonic saline solutions (HS)
Pulmosal 7% (pH +) sodium chloride inhalation solution was used for all studies except one where it was not available. Pulmosal is sterile, nonpyrogenic, preservative-free, and balanced to a pH of 7.4. In one study another 7% HS product for inhalation was utilized (subject 9).
| Study design
The study was approved by the University of Pittsburgh Institutional (ethics) Review Board (clinicaltrials.gov NCT02141191, U of P PRO14010272). All subjects signed informed consent. Adult subjects with CF were enrolled if they had one second forced expiratory Pulse oximetry was monitored throughout the night while the subjects slept and the tPAD operated continuously. During the sham visit, subjects wore the cannula as they did during the HS visit and the tPAD was powered on, but the nebulizer and the air pump were nonoperational and no air flowed through the cannula. Subjects who did not complete both nights were not included in the analysis and were replaced until a total of 12 subjects had completed both visits. | 1143
| MCC measurement-radiopharmaceutical delivery and imaging
non-absorbable particle with a mean diameter of approximately 300 nm. 17 In-DTPA is a hydrophilic small molecule (545.29 Da). 18 Aerosol delivery was performed for approximately 5 min. Afterward, a dynamic scan including 45 sequential 2 min images was performed followed by a Cobalt 57 transmission scan. Follow-up images were collected at t = 3 h (10 min image) and t = 6 h (30 min image). Three energy windows were recorded for each image (140, 210, and 245 kev). These correspond respectively to Tc99m, a mid-window between the lower and upper energy peaks of In111, and the upper peak of In111. Two different gamma cameras were used during the course of the study: a Siemens Symbia (seven studies) and a GE Discovery NM630 gamma camera (three studies). Two subjects used the Siemens camera on day 1 and the GE camera on day 2. All imaging was performed with subjects recumbent.
The primary outcome of the study was MCC as compared between HS and sham visits. Secondary outcomes included safety assessments, ABS, and results from Sino-Nasal Symptoms (SNOT-14)
and modified Leeds Sleep Evaluation Questionnaires (mLSEQ).
Questionnaires were presented to the study subjects at screening and on the mornings after HS and sham administration.
| MCC measurement-image analysis
Semi-automated imaged analysis was performed using a MATLAB script. Posterior images of the right lung were used. The left lung was not used to avoid interference from the stomach. The Co57 transmission scan was used to trace the right lung boundary which was then applied to the dynamic clearance scan sequence enabling "whole lung" radioactive counts to be measured in each energy window. Counts were adjusted for background, decay, and isotope spillover, as previously described. 9 The data were then normalized by starting counts and retention versus time curves were produced. Tc-SC counts were used to assess MCC. In-DTPA is cleared by both MCC and absorption. We calculated the absorption rate of DTPA (ABS) by subtracting the MCC rate measured using Tc-SC from the total clearance rate of In-DTPA. Previous studies have related ABS to ASL absorption, 16 and ABS responses to inhaled HS have been previously demonstrated in vivo. 9 A central right lung zone, defined as a rectangular area that had one-half the height and one-half the width of a rectangle that surrounded the lung perimeter, was placed on the medial border of the right lung at approximately mid-height to determine central lung counts.
| Assessments of safety and tolerability
Spirometry was assessed during screening, prior to tPAD use, and again after tPAD use and imaging. Pulse oximetry was measured every 2 h during tPAD use. A modified version of the Leeds Sleep Evaluation
Questionnaire was administered at screening and on the morning after sham and HS treatments. It includes 10 questions about sleep quality.
Subjects were administered a portion of the Sino-Nasal Outcome Test 3 | RESULTS Table 1 includes subjects who completed the study. Two subjects failed screening after experiencing >10% reduction from pre-dose TABLE 1 Age, gender, Pre Dose FEV1, and central to peripheral (C/P) deposition ratio for subjects who completed both study days intensity. There was no difference in pre-study FEV 1 between the study days (P = 0.76 by paired t-test). Table 2 and Fig. 1 include the results of whole lung MCC measurements made after the HS and sham nights. There were no significant differences in whole lung MCC associated with the HS therapy at any time point (for comparisons at t = 90 min, 3 h, and 6 h, P = 0.75, 0.38, and 0.64, respectively, by paired t-test). Table 3 and Fig. 3 compare whole lung ABS as measured the morning after the HS and sham nights. There were no significant differences in whole lung ABS associated with the HS therapy at t = 90 min or 6 h (P = 0.45, and 0.37, respectively, by paired t-test). At t = 3 h, study day differences approached significance with HS being associated with increased ABS (P = 0.09). Tables S3 and S4 List We considered the effect of radiopharmaceutical aerosol distribution on measurements of MCC and ABS using central to peripheral deposition ratio (C/P) as a gauge. Deposition was generally repeatable between test days (comparing C/P by paired t-test, P = 0.23.). Values are included in Table 1 . The average intrasubject difference in C/P between test days was 0.3 ± 0.2 (range 0-0.8). Intersubject differences were higher and the range of C/P values was 0.8-3.5. Subject 9 had highly central deposition on both testing days (C/P = 3.4, 3.5) and demonstrated higher MCC and lower ABS when compared to the other subjects. Linear relationships were indicated for both MCC and ABS versus C/P (MCC R 2 = 0.24, P = 0.01; ABS R 2 = 0.41, P = 0.001). These comparisons did not vary significantly if subject 9 was removed.
The slopes of these relationships are approximately 10(C/P) for MCC and −11(C/P) for ABS, thus a 0.5 increase in C/P would be associated with a 5% increase in MCC and a 5.5% decrease in 27-40 min), (P = 0.43, by paired t-test.
As shown in Table S5 , average FEV 1 decreased slightly on average during both sham and HS visits, as assessed before the beginning of the overnight treatment and during the next day in the afternoon after the completion of the imaging study (Δ FEV 1 HS: −48 mL ± 108 vs Sham:
−110 ± 147 mL, P = 0.14). These differences are not clinically significant. Average pulse oximetry readings were similar by subject during sham and HS nights (P = 0.21, paired t-test). Table S6 with inhaled HS in measurements made during and immediately after oral HS inhalation. 9 In explaining the outcomes here we must first consider the NaCl dose delivered to the airways by both tPAD and oral inhalation. Preclinical studies indicate that the tPAD emits 3.47 ± 0.41 mg of NaCl per minute or 1665 ± 196 mg NaCl over 8 h. Pulmonary deposition efficiency of the tPAD device was measured in awake healthy subjects using deposition scintigraphy techniques and was similar to that of the Pari LC Star nebulizer used for oral inhalation (38 ± 9% of emitted dose). 10 The delivery rate for the tPAD over an 8 h dosing interval is estimated at 632 mg or 1.31 mg/min. Oral aerosol delivery typically utilizes 4 mL loaded doses (280 mg of NaCl). Assuming that the emitted dose for oral delivery is 70% of loaded dose (30% losses within the nebulizer), with 38% pulmonary delivery efficiency and a 15 min delivery time, the total lung dose and delivery rate is 74.5 mg and 5 mg/min, respectively Thus NaCl delivery to the lung during a typical oral inhalation treatment occurs at a rate 3-4 times that provided by tPAD. Later studies of tPAD performance describe lower NaCl dosing rates. routes. Airway obstruction has been reported from generation 6 in CF. 24 Oral delivery rapidly increases ASL height in all three generations considered (7 through 9) and the effect was sustained for several hours.
Nasal delivery produces durable increases in ASL height in generation 7,
but not in the smaller airway generations, unless 14% saline is modeled.
Though our ability to accurately estimate airway dose is limited, these results indicate that dosing rates from the tPAD for airways distal to generations 8-10 may well be less than what is required to overcome active Na+ absorption by the airway epithelium, preventing the development of osmotic gradients across the ASL. Deposition scintigraphy studies also indicated increased peripheral deposition with tPAD which may mean even less of the dose was delivered to the large airways which are most likely to dominate the MCC measurement. 10, 11 Peripheral deposition was likely driven by the small delivered droplet sizes and the slower respiration patterns that occur during sleep. 25 The tPAD device was safe and well tolerated during overnight use.
There were no serious adverse events and all adverse events reported were of mild or moderate intensity. Only one subject discontinued overnight use. All other subjects who began the study nights completed the 8 h treatment. There were no significant differences in overnight pulse oximetry and changes in study day FEV1 were small and similar between HS and sham. There was no difference between the average self-assessed quality of sleep between the sham and the HS nights. Results of the modified SNOT-14 indicated significant worsening in two symptom categories with HS (need to blow nose and runny nose). Other categories were similar.
In summary, the overnight delivery of inhaled 7% HS via nasal cannula using the tPAD device was safe and well tolerated but did not alter measurements of MCC or ABS made the morning after delivery.
Given that acute increases in MCC and decreases in ABS have been previously demonstrated after oral inhalation, the most likely cause for the negative result is under-dosing relative to the rate of active transport of salt from the airways.
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